{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T16:21:16Z","timestamp":1780849276795,"version":"3.54.1"},"reference-count":8,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.1182\/blood.2023022822","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:31:49Z","timestamp":1706805109000},"page":"380-382","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Old rivals become new friends"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-4494","authenticated-orcid":false,"given":"Philippe","family":"Rousselot","sequence":"first","affiliation":[{"name":"University of Versailles Paris-Saclay"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2024020116313911600_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2024020116313911600_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","article-title":"From preclinical development to success in B-cell acute lymphoblastic leukemia","volume":"3","author":"Wynne","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2024020116313911600_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024020116313911600_bib4","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2024020116313911600_bib8","doi-asserted-by":"crossref","unstructured":"Stelljes\n              M\n            , RaffelS, AlakelN, . Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol. Published online 26 October 2023. https:\/\/doi.org\/10.1200\/JCO.23.00546.","DOI":"10.1200\/JCO.23.00546"},{"issue":"suppl 1","key":"2024020116313911600_bib5","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1182\/blood-2022-157937","article-title":"Study of feasibility and effectiveness of inotuzumab ozogamicin, 2022 study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation [abstract]","volume":"140","author":"Marconi","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2024020116313911600_bib6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2024020116313911600_bib7","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/380\/2210904\/blood_bld-2023-022822-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/380\/2210904\/blood_bld-2023-022822-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:31:54Z","timestamp":1706805114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/5\/380\/514729\/Old-rivals-become-new-friends"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022822","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}